Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as an investment opportunity by projecting its future cash flows and then discounting them to today's value. I will use the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Alnylam Pharmaceuticals

### Is Alnylam Pharmaceuticals fairly valued?

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:

#### 10-year free cash flow (FCF) forecast

2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |

Levered FCF ($, Millions) | $-819.4m | $-498.5m | $-273.5m | $275.5m | $422.9m | $584.7m | $746.1m | $896.4m | $1.0b | $1.1b |

Growth Rate Estimate Source | Analyst x5 | Analyst x2 | Analyst x2 | Analyst x2 | Est @ 53.49% | Est @ 38.26% | Est @ 27.6% | Est @ 20.14% | Est @ 14.92% | Est @ 11.26% |

Present Value ($, Millions) Discounted @ 10.16% | $-743.8 | $-410.8 | $-204.6 | $187.1 | $260.7 | $327.2 | $379.0 | $413.3 | $431.2 | $435.5 |

*("Est" = FCF growth rate estimated by Simply Wall St)* **Present Value of 10-year Cash Flow (PVCF)**= $1.1b

After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 10-year government bond rate of 2.7%. We discount the terminal cash flows to today's value at a cost of equity of 10.2%.

**Terminal Value (TV)** = FCF_{2029} Ã— (1 + g) Ã· (r â€“ g) = US$1.1b Ã— (1 + 2.7%) Ã· (10.2% â€“ 2.7%) = US$16b

**Present Value of Terminal Value (PVTV)** = TV / (1 + r)^{10} = $US$16b Ã· ( 1 + 10.2%)^{10} = $6.02b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is $7.10b. In the final step we divide the equity value by the number of shares outstanding. **This results in an intrinsic value estimate of $66.62**. Relative to the current share price of $76.36, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

### Important assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Alnylam Pharmaceuticals as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 10.2%, which is based on a levered beta of 1.247. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

### Next Steps:

Whilst important, DCF calculation shouldnâ€™t be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Alnylam Pharmaceuticals, I've compiled three relevant factors you should further examine:

**Financial Health**: Does ALNY have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.**Future Earnings**: How does ALNY's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.**Other High Quality Alternatives**: Are there other high quality stocks you could be holding instead of ALNY? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQ every day. If you want to find the calculation for other stocks just search here.

*We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.*

*If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.*